Get the Stockscreener App
4.38
1.15%
0.05
After Hours:
4.47
0.09
+2.05%
Scisparc Ltd stock is traded at $4.38, with a volume of 144.70K.
It is up +1.15% in the last 24 hours and up +96.41% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$4.33
Open:
$4.21
24h Volume:
144.70K
Relative Volume:
0.03
Market Cap:
$2.34M
Revenue:
$1.75M
Net Income/Loss:
$-5.68M
P/E Ratio:
-0.8989
EPS:
-4.8726
Net Cash Flow:
-
1W Performance:
-27.36%
1M Performance:
+96.41%
6M Performance:
+1,453%
1Y Performance:
+1,903%
1-Day Range:
$4.21
$4.54
1-Week Range:
$4.14
$5.90
52-Week Range:
$0.197
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
4.38 | 7.02M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc And AutoMax Call Off Merger - Sahm
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors - GlobeNewswire
SciSparc Ltd. cancelled the acquisition of remaining stake in Automax Motors Ltd. - MarketScreener
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
What candlestick patterns are forming on SciSparc Ltd.July 2025 Volume & Smart Investment Allocation Insights - newser.com
Why SciSparc Ltd. stock remains on buy listsOptions Play & Free Growth Oriented Trading Recommendations - newser.com
SciSparc Ltd. Terminates Merger Agreement with AutoMax Motors - TipRanks
SciSparc, AutoMax Motors mutually agree to terminate merger - TipRanks
Scisparc Ltd. announces framework agreement regarding merger with AutoMax Motors - MarketScreener
SciSparc Ltd. and AutoMax Motors Ltd. Announce Mutual Termination of Merger and Loan Repayment Agreement - Quiver Quantitative
SciSparc and AutoMax Motors terminate merger agreement - Investing.com
$4.25M Repayment Plan: SciSparc & AutoMax Mutually Terminate Merger; $2M in Monthly Repayments - Stock Titan
SciSparc Shareholders Approve Merger with AutoMax - MSN
How SciSparc Ltd. stock compares to market leadersAnalyst Upgrade & Verified Entry Point Signals - newser.com
Backtesting results for SciSparc Ltd. trading strategies2025 Market Overview & Capital Efficiency Focused Strategies - newser.com
SciSparc’s subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29% - MSN
SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition - Investing.com
SciSparc Surge: Analyzing Latest Developments - StocksToTrade
SciSparc Shares Surge: Time to Invest? - timothysykes.com
Morning Market Movers: SPRC, APDN, EPSM, WOLF See Big Swings - RTTNews
SciSparc’s MitoCareX Merger with N2OFF Approved by Shareholders - TipRanks
SciSparc Stocks Surge 50% In Pre-Market After N2OFF Approves MitoCareX Acquisition - Nasdaq
N2OFF shareholders approve acquisition of MitoCareX Bio from SciSparc By Investing.com - Investing.com Nigeria
N2OFF shareholders approve acquisition of SciSparc subsidary - TipRanks
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s - GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
N2OFF shareholders approve acquisition of MitoCareX Bio from SciSparc - Investing.com India
SciSparc: N2OFF Shareholders Approve Merger with SciSparc’s Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - GlobeNewswire
SciSparc Plans to Use Quantum Computers to Model 3D Proteins For AI Drug Discovery - The Quantum Insider
What analysts say about SciSparc Ltd stockMarket Correction Analysis & Buy Sell Timing Alerts - earlytimes.in
SciSparc Ltd. Announces Warrant Exercise Agreement - MSN
Published on: 2025-09-26 06:35:52 - newser.com
SPRC Rockets 59% After “Quantum Leap”: What Really Drove SciSparc’s Two‑Day Surge (Sept. 25–26) — And What Comes Next - ts2.tech
N2OFF stockholders approve MitoCareX Bio acquisition By Investing.com - Investing.com Nigeria
Biotech Small Caps Catch Fire On Clinical And Tech News - Finimize
N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer - The Manila Times
N2OFF Shareholders Approve Acquisition of MitoCareX Bio - MarketScreener
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
4.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):